BioWorld

May 3, 2005

View Archived Issues

GSK Buying Corixa: $300M Brings MPL Facility, More

Vaccine partner GlaxoSmithKline plc plans to buy Corixa Corp. for $300 million in cash, paying $4.40 per share - a 48 percent premium to the closing price on April 28, the day before the deal was made public. (BioWorld Today) Read More

Flurizan Misses Major Phase II Endpoints, But Positives Seen

Read More

Biotech Model Broken; Now What Can Be Done About It?

Read More

Conforma Adding $11M To Series C For Hsp90 Drugs

Read More

CTI Aims For Xyotax NDA Despite Missed Endpoints

Read More

Other News To Note

Read More

Appointments And Advancements

Read More